Qi-Jing Li is a Distinguished Principal Scientist at the Institute of Molecular and Cell Biology (IMCB) and Singapore Immunology Network (SIgN). He holds a B.S. in Biochemistry and Molecular Biology from Peking University.

As an academic scientist, Qi-Jing has developed new technology platforms for immunogenomics profiling, engineered various cell therapy tools, and designed and aided numerous phase I/II therapeutical trials against various cancers.

Dr. Qi-Jing LI's research focuses on translational T cell biology and therapeutics, with an emphasis on understanding how tumors evade immune surveillance and developing innovative strategies to enhance T cell-mediated anti-tumor immunity.

Qi-Jing Li. IMCB & SIgN, A*STAR Singapore. Verified email at IMCB.A-STAR.edu.sg. Molecular Immunology and Immunotherapy. Articles Cited by Public access Co-authors. ... Cited by. Cited by. Year; miR-181a is an intrinsic modulator of T cell sensitivity and selection. QJ Li, J Chau, PJR Ebert, G Sylvester, H Min, G Liu, R Braich, ... Cell 129 (1 ...

Aiming to develop new immunotherapies against cancers, and interconnected with clinical trials executed by clinician collaborators and immunogenomic tools developed in house, my research program rests on three pillars – the T cell, the Tumor Microenvironment, and Immunotherapy. We regard the tumor as an acquired immunosuppressive organ.

As an academic scientist, Qi-Jing has developed new technology platforms for immunogenomics profiling, engineered various cell therapy tools, and designed and aided numerous phase I/II therapeutical trials against various cancers.

Recent clinical success in cancer immunotherapy, including immune checkpoint blockades and chimeric antigen receptor T cells, have settled a long-debated question in the field: whether tumors can be recognized and eliminated by our own …

Qi-Jing’s early research at Stanford focused on TCR antigen recognition and signaling sensitivity. He made a series of key contributions in defining the minimal subunit, rate-limiting step, and sensitivity controls of TCR activation.

Recent clinical success in cancer immunotherapy, including immune checkpoint blockades and chimeric antigen receptor T cells, have settled a long-debated question in the field: whether tumors can be recognized and eliminated by our own …